{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:29:57Z","timestamp":1783132197187,"version":"3.54.6"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202102080057"],"award-info":[{"award-number":["202102080057"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2021A1515010640"],"award-info":[{"award-number":["2021A1515010640"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073427"],"award-info":[{"award-number":["82073427"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020084","name":"Guangzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaad.2022.01.039","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T21:21:05Z","timestamp":1643750465000},"page":"1236-1245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis in a cohort of patients"],"prefix":"10.1016","volume":"86","author":[{"given":"Suiting","family":"Ao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jipang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhua","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coco","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiande","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2022.01.039_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00134-009-1659-1","article-title":"Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes","volume":"36","author":"Struck","year":"2010","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.jaad.2022.01.039_bib2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bjd.19893","article-title":"Supportive care in the acute phase of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus","volume":"185","author":"Br\u00fcggen","year":"2021","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2022.01.039_bib3","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/ijd.14426","article-title":"A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens\u2013Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016","volume":"58","author":"Chan","year":"2019","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.01.039_bib4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40257-019-00443-9","article-title":"Association of early systemic corticosteroid therapy with mortality in patients with Stevens\u2013Johnson syndrome or toxic epidermal necrolysis: a retrospective cohort study using a nationwide claims database","volume":"20","author":"Morita","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.01.039_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2133.1976.tb00824.x","article-title":"Erythema multiforme in children. Response to treatment with systemic corticosteroids","volume":"95","author":"Rasmussen","year":"1976","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.01.039_bib6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jaad.2022.01.039_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/09546634.2019.1577548","article-title":"Biologic TNF-alpha inhibitors in the treatment of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a systemic review","volume":"31","author":"Zhang","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2022.01.039_bib8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.01.039_bib9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/1203475421993779","article-title":"A systematic review of efficacy and safety of monotherapy and combination therapy with biologic for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"25","author":"Sachdeva","year":"2021","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.jaad.2022.01.039_bib10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2022.01.039_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12016-021-08859-0","article-title":"Current perspectives on severe drug eruption","volume":"61","author":"Zhang","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2022.01.039_bib12","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","article-title":"Increased soluble Fas ligand levels in patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis preceding skin detachment","volume":"122","author":"Murata","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2022.01.039_bib13","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2022.01.039_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13601-018-0199-6","article-title":"Diverse expression of TNF-alpha and CCL27 in serum and blister of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"8","author":"Wang","year":"2018","journal-title":"Clin Transl Allergy"},{"issue":"5","key":"10.1016\/j.jaad.2022.01.039_bib15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.01.039_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.01.039_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/hep.28270","article-title":"Drug-induced liver injury associated with Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases","volume":"63","author":"Devarbhavi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jaad.2022.01.039_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens\u2013Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.01.039_bib19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaad.2021.04.082","article-title":"Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"85","author":"Duplisea","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.01.039_bib20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jdcr.2017.05.006","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) successfully treated with tumor necrosis factor-alpha inhibitor","volume":"3","author":"Leman","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2022.01.039_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000388","article-title":"Rapid recovery of postnivolumab vemurafenib-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome after tocilizumab and infliximab administration","volume":"8","author":"Maximova","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.jaad.2022.01.039_bib22","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1111\/jdv.17540","article-title":"Acute generalized exanthematous pustulosis overlapping with toxic epidermal necrolysis successfully treated with etanercept","volume":"35","author":"Ridha","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2022.01.039_bib23","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jid.2017.01.003","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology-thirty years of progress but still much to be done","volume":"137","author":"Stern","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2022.01.039_bib24","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Research"},{"issue":"6","key":"10.1016\/j.jaad.2022.01.039_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2022.01.039_bib26","first-page":"236","article-title":"Serum IFN-gamma-inducible chemokines CXCL9 and CXCL10 are elevated in non-immediate drug hypersensitivity reactions","volume":"34","author":"Wang","year":"2016","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2022.01.039_bib27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/toxins6010194","article-title":"Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions","volume":"6","author":"Su","year":"2014","journal-title":"Toxins (Basel)"},{"issue":"3","key":"10.1016\/j.jaad.2022.01.039_bib28","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2020.06.043","article-title":"Acute pancreatic injuries: A complication of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis associated with cytotoxic immunocell activation","volume":"84","author":"Gao","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2022.01.039_bib29","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1007\/s00262-006-0149-3","article-title":"Macrophage inflammatory protein (MIP)1alpha and MIP1beta differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy","volume":"55","author":"Nath","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.jaad.2022.01.039_bib30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood-2002-07-2305","article-title":"MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity","volume":"101","author":"Lillard","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jaad.2022.01.039_bib31","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/1346-8138.15058","article-title":"Successful treatment of interstitial lung disease related to Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis overlap with etanercept: a case report and published work review","volume":"46","author":"Wang","year":"2019","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.01.039_bib32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/apa.13319","article-title":"Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis","volume":"105","author":"Kahn","year":"2016","journal-title":"Acta Paediatr"},{"issue":"1","key":"10.1016\/j.jaad.2022.01.039_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/03009742.2017.1290822","article-title":"Tumour necrosis factor-\u03b1\/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis","volume":"47","author":"Berthold","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2022.01.039_bib34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood.V97.1.14","article-title":"Interleukin 15: biology and relevance to human disease","volume":"97","author":"Fehniger","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jaad.2022.01.039_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/000155599750011679","article-title":"Interleukin-15 is not a constitutive cytokine in the epidermis, but is inducible in culture or inflammatory conditions","volume":"79","author":"Han","year":"1999","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2022.01.039_bib36","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s10067-020-05190-5","article-title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment","volume":"39","author":"Soy","year":"2020","journal-title":"Clin Rheumatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222001712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222001712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:28Z","timestamp":1759273288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222001712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0190962222001712"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.01.039","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis in a cohort of patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.01.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}